Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

124.74 +4.03 (+3.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy
NVTA stock tumbled yesterday amid a report that the firm could declare bankruptcy soon. The shares were halted for news pending. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures. 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Pinterest, Checkpoint Therapeutics And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
New Study Validates Signatera™ in Endometrial Cancer
From Natera, Inc.
Via Business Wire
Expert Ratings For Natera
Via Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
From Natera, Inc.
Via Business Wire
The Analyst Landscape: 8 Takes On Natera
Via Benzinga
The Latest Analyst Ratings for Natera
Via Benzinga
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
From Natera, Inc.
Via Business Wire
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
From Natera, Inc.
Via Business Wire
Natera Acquires Reproductive Health Assets from Invitae
From Natera, Inc.
Via Business Wire
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
From Natera, Inc.
Via Business Wire
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
The company must pay $57 million in damages, but that's far less than expected. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market... 
Via Benzinga
Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as... 
Via Benzinga
Topics Stocks
Exposures US Equities
Natera Provides Update on Ravgen Trial
From Natera, Inc.
Via Business Wire
Bull of the Day - NeoGenomics
But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context. 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
From Natera, Inc.
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit
Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from  
Via Benzinga
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
From Natera, Inc.
Via Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
From Natera, Inc.
Via Business Wire
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.